Zomedica initiated with an Outperform at Noble Capital

Noble Capital initiated coverage of Zomedica (ZOM) with an Outperform rating and 25c price target The company makes and sells veterinary therapeutic devices and diagnostics used to diagnose and treat animals ranging from horses to cats, dogs, and other pets, the analyst tells investors. Zomedica has grown by acquiring complementary businesses that broaden its product line and leverage its existing infrastructure, notes the firm, which values the stock based on its estimate of the company’s FY27 revenues.